Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech,” which examines how late-stage drug development assets are increasingly influencing valuation in the biopharma sector. The editorial, supported by analysis from McKinsey & Company, notes that companies tend to realize the majority of value creation as products approach commercialization, reflecting reduced risk and clearer revenue visibility. This trend is directly relevant to Oncotelic’s oncology-focused pipeline and strategic development approach.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.
The full press release can be viewed at https://nnw.fm/42BlH. For more information about Oncotelic, visit the company’s newsroom at https://nnw.fm/OTLC.
